PropertyValue
?:abstract
  • The December 2019 outbreak of a novel respiratory virus, SARS-CoV-2, has become an ongoing global pandemic due in part to the challenge of identifying symptomatic, asymptomatic, and pre-symptomatic carriers of the virus. CRISPR diagnostics can augment gold-standard PCR-based testing if they can be made rapid, portable, and accurate. Here, we report the development of an amplification-free CRISPR-Cas13a assay for direct detection of SARS-CoV-2 from nasal swab RNA that can be read with a mobile phone microscope. The assay achieved ∼100 copies/µL sensitivity in under 30 min of measurement time and accurately detected pre-extracted RNA from a set of positive clinical samples in under 5 min. We combined crRNAs targeting SARS-CoV-2 RNA to improve sensitivity and specificity and directly quantified viral load using enzyme kinetics. Integrated with a reader device based on a mobile phone, this assay has the potential to enable rapid, low-cost, point-of-care screening for SARS-CoV-2.
is ?:annotates of
?:creator
?:journal
  • Cell
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy
?:type
?:who_covidence_id
  • #956964
?:year
  • 2020

Metadata

Anon_0  
expand all